TABLE 3.
Relationship between cancers and eight potential drugs based on CTD.
| Drugs | Disease | Inference Score |
| Nadolol | Stomach Neoplasms | 5.67 |
| Gastro-enteropancreatic neuroendocrine tumor | 4.58 | |
| Prostatic Neoplasms | 4.43 | |
| Leukemia-Lymphoma, Adult T-Cell | 4.14 | |
| Mesothelioma, Malignant | 3.95 | |
| Glioma | 3.83 | |
| Colonic Neoplasms | 3.7 | |
| Neoplasms, Experimental | 3.42 | |
| Carcinoma, Hepatocellular | 3.38 | |
| Carcinoma, Non-Small-Cell Lung | 3.31 | |
| Liver Neoplasms | 3.31 | |
| Mammary Neoplasms, Experimental | 3.18 | |
| Lung Neoplasms | 2.90 | |
| Breast Neoplasms | 2.71 | |
| Adiphenine | Barrett Esophagus | 5.74 |
| Osteosarcoma | 5.13 | |
| Esophageal Neoplasms | 4.81 | |
| Adenocarcinoma | 4.44 | |
| Chlorhexidine | Hematologic Neoplasms | 4.38 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4.02 | |
| Esophageal Squamous Cell Carcinoma | 3.75 | |
| Carcinoma, Hepatocellular | 2.89 | |
| Trimethobenzamide | Barrett Esophagus | 5.28 |
| Osteosarcoma | 4.67 | |
| Esophageal Neoplasms | 4.35 | |
| Adenocarcinoma | 3.99 | |
| Felbinac | Thyroid Neoplasms | 3.69 |
| Glioblastoma | 3.59 | |
| Adenocarcinoma | 3.25 | |
| Colonic Neoplasms | 3.18 | |
| Neoplasm Invasiveness | 3.12 | |
| Stomach Neoplasms | 3.07 | |
| Neoplasms | 3.06 | |
| Lung Neoplasms | 2.94 | |
| Breast Neoplasms | 2.71 | |
| Clemastine | Carcinoma, Ovarian Epithelial | † |
| Colorectal Neoplasms | 3.94 | |
| Cell Transformation, Neoplastic | 3.72 | |
| Colonic Neoplasms | 3.70 | |
| Carcinoma, Hepatocellular | 3.60 | |
| Neoplasms | 3.58 | |
| Ajmaline | Osteosarcoma | 3.52 |
| Cell Transformation, Neoplastic | 3.17 | |
| Colonic Neoplasms | 3.15 | |
| Neoplasms | 3.05 | |
| Prostatic Neoplasms | 2.50 | |
| Breast Neoplasms | 2.47 | |
| Carbimazole | Colonic Neoplasms | 3.56 |
†, therapeutic value.